Study | Inducer | Victim (Dose) | Dose Stagger | n | AUC (mg/L.h) | AUCi (mg/L.h) | 1/AUC Ratio |
---|---|---|---|---|---|---|---|
Carbamazepine | |||||||
Ucar et al., 2004 | CBZ (200 mg daily for 2 days; 300 mg twice a day for 12 days) | SMV (80 mg) | 0 | 12 | 0.089 (58.1) | 0.023 (56.7) | 3.93 |
Andreasen et al., 2007 | CBZ (200 mg twice a day for 2 days; 400 mg twice a day for 14 days) | QND (200 mg) | 0a | 10 | 5.12 (n/a) | 1.98 (n/a) | 2.57 |
Vlase et al., 2011 | CBZ (400 mg daily for 16 days) | ZOL (5 mg) | 0a | 18 | 0.235 (70.4) | 0.102 (58.1) | 2.31 |
Phenytoin | |||||||
Data et al., 1976 | Dose adjusted to maintain plasma PHY conc 10–20 μg/ml | QND (300 mg) | 0a | 2 | 12.6 (10.3, 15.0) | 5.53 (4.24, 6.82) | 2.28 |
Phenobarbital | |||||||
Schellens et al., 1989 | PHB (100 mg daily for 8 days) | NIF (20 mg) | 12a | 15 | 0.343 (36.4) | 0.135 (57.8) | 2.54 |
Data et al., 1976 | Dose adjusted to maintain plasma PHB conc. 10–20 μg/ml | QND (300 mg) | 0a | 2 | 12.0 (9.33, 14.6) | 4.10 (3.19, 5.00) | 2.92 |
AUC, area under the curve; CBZ, carbamazepine; n/a, not available; PHB, phenobarbital; PHY, phenytoin; QND, quinidine; SMV, simvastatin; ZOL, zolpidem.
↵a Ambiguous.